Gilead Sciences: It’s More Than Hepatitis C…But Not Enough More For Now
May 20, 2016 at 15:41 PM EDT
As concerns about Gilead Sciences ( GILD ) mount, Maxim's Jason Kolbert are bullish on the biotech giant's HIV franchise but not enough to change his Hold rating on the stock :
